Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tetra Bio Pharma Inc (TSX: TBP )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Mar 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tetra Bio Pharma Inc

Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003
The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral... 
Via TheNewswire.com
Exposures COVID-19
Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis
MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and... 
Via TheNewswire.com
The Power Play by The Market Herald Releases New Interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold Discussing Their Latest News
Via ACCESSWIRE
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
From Akanda Corp. and Tetra Bio-Pharma
Via Business Wire
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021
LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will... 
From Stock News Now
Via AccessWire
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial... 
Via Benzinga
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 - The... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 /... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures COVID-19 Cannabis Intellectual Property
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra"... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in... 
From Tetra Bio-Pharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
- First clinical study to assess cannabis as an alternative to morphine - Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial - Export permit received from Health Canada for... 
From Tetra Bio-Pharma
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
- Tetra strengthens its intellectual property portfolio - Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc.... 
From Tetra Bio-Pharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
- REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug - The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 /... 
From Tetra Bio-Pharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.